Editorial
doi: 10.3109/0284186X.2013.821206.
What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?
Affiliations
- PMID: 24102178
- DOI: 10.3109/0284186X.2013.821206
Item in Clipboard
Editorial
What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?
Acta Oncol.
2013 Nov.
No abstract available
Comment on
-
Population-based study on use of chemotherapy in men with castration resistant prostate cancer.Acta Oncol. 2013 Nov;52(8):1593-601. doi: 10.3109/0284186X.2013.770164. Epub 2013 Feb 21. Acta Oncol. 2013. PMID: 23427879 Free PMC article.
Similar articles
-
The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer.Eur Urol. 2015 Jan;67(1):30-32. doi: 10.1016/j.eururo.2014.07.030. Epub 2014 Aug 6. Eur Urol. 2015. PMID: 25108578 No abstract available.
-
Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15. J Urol. 2014. PMID: 23954373
-
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9. Lancet Oncol. 2017. PMID: 29033099 Clinical Trial.
-
Sequencing of agents for castration-resistant prostate cancer.Oncology (Williston Park). 2013 Nov;27(11):1144-9, 1154-8. Oncology (Williston Park). 2013. PMID: 24575543 Review.
-
Drug therapies for metastatic castration-resistant prostate cancer.Future Oncol. 2015;11(17):2395-403. doi: 10.2217/fon.15.168. Epub 2015 Aug 14. Future Oncol. 2015. PMID: 26274603 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources